|Bid||0.303 x 200|
|Ask||0.306 x 1000|
|Day's Range||0.295 - 0.328|
|52 Week Range||0.260 - 2.280|
|PE Ratio (TTM)||-0.49|
|Earnings Date||Nov 6, 2017 - Nov 10, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||5.50|
The The Woodlands, Texas-based company said it had a loss of 8 cents per share. The biopharmaceutical company posted revenue of $7,000 in the period. The company's shares closed at 35 cents. A year ago, ...
THE WOODLANDS, Texas, Aug. 14, 2017-- Repros Therapeutics Inc. ® today announced financial results for the second quarter ended June 30, 2017.. Net loss for the three month period ended June 30, 2017, ...
Lack of revenues in Repros Therapeutics' (RPRX) product portfolio could be a concern. But the company's most advanced pipeline candidates -- enclomiphene and Proellex -- might better its results in Q2.